Online Supplementary information for the manuscript entitled Rac1 regulation of the surface expression of PAR1 and responsiveness to thrombin in vascular smooth muscle cells

Materials Thrombin (bovine plasma, 1880 NIH units/mg protein) was purchased from Sigma (St. Louis, MO, U.S.A.). Simvastatin, fluvastatin and pravastatin were supplied by Merck & Co. (Rahway, N.J., U.S.A.), Novartis Pharma Inc. (Tokyo, Japan) and Sankyo Co. (Tokyo, Japan), respectively. TFLLR-NH2 (PAR1-activating peptide) and GYPGKFNH2 (PAR4-activating peptide) were purchased from Bachem (Bubendorf, Switzerland). Geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) were purchased from Sigma (St. Louis, MO, U.S.A.). Geranylgeranyl transferase inhibitor (GGTI-298) and farnesyl transferase inhibitor (FTI-277) were purchased from Calbiochem (San Diego, U.S.A.). The antibodies and their source were as follows: phycoerythrine-conjugated anti-PAR1 antibody WEDE15 (Immunotech, Marseille, France), anti-(His)6 antibody (Qiagen, Hilden, Germany), Anti-PAR1 antibody (sc-5605, Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.), horse radish peroxidaseconjugated anti-mouse IgG (Sigma) and horse radish peroxidase-conjugated anti-rabbit IgG (Vector Laboratories, Burlingame, CA, U.S.A.). Oligonucleotides was synthesized by Hokkaido System Sciences (Sapporo, Japan).